{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:36:47Z","timestamp":1788194207995,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.7759\/cureus.95938","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:06:23Z","timestamp":1762088783000},"source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Roaa","family":"Mohamed Ali Elbashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Elbashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Urimuke Basake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Zakaria Ahmed Mohieldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"I A Elhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ebrahim Mohamed Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waad","family":"Gase Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Abdelrahim Mohamed Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2022.100456","article-title":"Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis","volume":"35","author":"Vosoughi K","year":"2022","unstructured":"Vosoughi K, Roghani RS, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis. Obes Med. 2022, 35:100456. 10.1016\/j.obmed.2022.100456","journal-title":"Obes Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21107","article-title":"GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond","volume":"23","author":"Ryan D","year":"2015","unstructured":"Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015, 23:1119-29. 10.1002\/oby.21107","journal-title":"Obesity (Silver Spring)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/a-1844-1176","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo X","year":"2022","unstructured":"Guo X, Zhou Z, Lyu X, et al.. The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022, 54:458-71. 10.1055\/a-1844-1176","journal-title":"Horm Metab Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong HJ","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, et al.. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025, 48:292-300. 10.2337\/dc24-1678","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo EM","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ, et al.. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025, 31:278-85. 10.1038\/s41591-024-03327-6","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan BM","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, et al.. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024, 12:631-42. 10.1016\/S2213-8587(24)00182-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey WT","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022, 28:2083-91. 10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"13","author":"Kadowaki T","year":"2025","unstructured":"Kadowaki T, Kiyosue A, Shingaki T, et al.. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2025, 13:384-96. 10.1016\/S2213-8587(24)00377-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"26","author":"Knop FK","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, et al.. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 26:705-19. 10.1016\/S0140-6736(23)01185-6","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15407","article-title":"Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"26","author":"Li Y","year":"2024","unstructured":"Li Y, Cheng Z, Lu W, et al.. Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Obes Metab. 2024, 26:1057-68. 10.1111\/dom.15407","journal-title":"Diabetes Obes Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00164-0","article-title":"Once-weekly semaglutide 2\u00b74 mg in an Asian population with obesity, defined as BMI \u226525 kg\/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Lim S","year":"2025","unstructured":"Lim S, Buranapin S, Bao X, et al.. Once-weekly semaglutide 2\u00b74 mg in an Asian population with obesity, defined as BMI \u226525 kg\/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025, 13:838-47. 10.1016\/S2213-8587(25)00164-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden TA","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021, 325:1403-13. 10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden TA","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023, 29:2909-18. 10.1038\/s41591-023-02597-w","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao L","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al.. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024, 332:551-60. 10.1001\/jama.2024.9217","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-025-00726-z","article-title":"The efficacy and safety of GLP-1 RAs in the modification of cardiovascular morbidity in patients with obesity without diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials involving 32,884 patients","volume":"25","author":"Tanashat M","year":"2025","unstructured":"Tanashat M, Al-Ajlouni YA, Abuelazm M, et al.. The efficacy and safety of GLP-1 RAs in the modification of cardiovascular morbidity in patients with obesity without diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials involving 32,884 patients. Am J Cardiovasc Drugs. 2025, 25:491-518. 10.1007\/s40256-025-00726-z","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can J","year":"2024","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2024, 38:784-93. 10.1038\/ijo.2013.162","journal-title":"Int J Obes (Lond)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06144-1","article-title":"Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"67","author":"Karagiannis T","year":"2024","unstructured":"Karagiannis T, Malandris K, Avgerinos I, et al.. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024, 67:1206-22. 10.1007\/s00125-024-06144-1","journal-title":"Diabetologia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne LJ","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025, 393:26-36. 10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despr\u00e9s JP","year":"2006","unstructured":"Despr\u00e9s JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006, 444:881-7. 10.1038\/nature05488","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424904-glucagon-like-peptide-1-glp-1-receptor-agonists-in-obese-patients-without-diabetes-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:06:23Z","timestamp":1762088783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424904-glucagon-like-peptide-1-glp-1-receptor-agonists-in-obese-patients-without-diabetes-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.95938","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,2]]}}}